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Factor V Leiden (F5 L ) is a common genetic risk factor for venous thromboembolism in humans. We conducted a sensitized N-ethyl-Nnitrosourea (ENU) mutagenesis screen for dominant thrombosuppressor genes based on perinatal lethal thrombosis in mice homozygous for ), suggesting that Actr2 p.R258G is thrombosuppressive. CRISPR/Cas9 experiments to generate an independent Actr2 knockin/knockout demonstrated that Actr2 haploinsufficiency is lethal, supporting a hypomorphic or gain-of-function mechanism of action for Actr2 p.R258G
. Our findings identify F8 and the Tfpi/F3 axis as key regulators in determining thrombosis balance in the setting of F5 L and also suggest a role for Actr2 in this process.
venous thromboembolism | Factor V Leiden | ENU mutagenesis | tissue factor pathway inhibitor | genetic screen V enous thromboembolism (VTE) is a common disease that affects 1-3 per 1,000 individuals each year (1) . VTE susceptibility exhibits a complex etiology involving contributions of both genes and environment. Genetic risk factors explain ≈60% of the overall risk for VTE (2) . Recent large-scale genome-wide association studies (GWAS) confirmed ABO, F2 F5, F11, FGG, and PROCR as thrombosis susceptibility genes, with only two additional novel loci, TSPAN15 and SLC44A2, identified (3-6), leaving the major component of VTE genetic risk still unexplained.
The Factor V Leiden variant (F5 L ) is a common inherited risk factor for VTE with an average allele frequency of 3.5% in the European population (7) (8) (9) . F5 L is estimated to account for up to 25% of the genetically attributable thrombosis risk in this population (7) . However, penetrance is incomplete, with only ∼10% of F5 L heterozygotes developing thrombosis in their lifetimes. The severity of thrombosis also varies widely among affected individuals (10) , limiting the clinical utility of F5 L genotyping in the management of VTE (11) . The incomplete penetrance and variable expressivity of thrombosis among F5
L patients can at least partially be explained by genetic interactions between F5 L and other known thrombotic risk factors such as hemizygosity for antithrombin III or proteins C or S, as well as the common prothrombin 20210 polymorphism (10, 12, 13). However, <2% of F5 L heterozygotes would be expected to coinherit a mutation at one or more of these loci, suggesting that a large number of additional genetic risk factors for VTE and/or modifiers of F5 L remain to be identified (3, 10) . Mice carrying the orthologous F5 L mutation exhibit a mild to moderate prothrombotic phenotype closely mimicking the human disorder (14) . We previously reported a synthetic lethal interaction
) and hemizygosity for tissue factor pathway inhibitor (Tfpi ) succumb to widespread, systemic thrombosis in the immediate perinatal period (15) .
N-ethyl-N-nitrosourea (ENU) mutagenesis in mice has been used effectively to identify novel genes involved in a number of biological processes (16, 17) . ENU-induced germline mutations transmitted from a mutagenized male mouse (G0) occur at ∼1.5 mutations per megabase, at least 50-fold higher than the endogenous background mutation rate (18) . Several previous reports have successfully applied an existing phenotype as a sensitizer to identify modifier genes. A dominant suppressor screen in Mecp2-deficient mice (Rett syndrome) identified a mutation in squalene epoxidase (Sqle) as a heritable suppressor, resulting in prolonged survival and amelioration of neurologic manifestations (19) . Other successful sensitized screens include analysis of mouse mutants predisposed to diabetic nephropathy (20) , a screen in Sox10 haploinsufficient mice identifying the Gli3 gene as a modifier of neurocristopathy Significance Venous thromboembolism (VTE) is a common disease characterized by the formation of inappropriate blood clots. Inheritance of specific genetic variants, such as the Factor V Leiden polymorphism, increases VTE susceptibility. However, only ∼10% of people inheriting Factor V Leiden develop VTE, suggesting the involvement of other genes that are currently unknown. By inducing random genetic mutations into mice with a genetic predisposition to VTE, we identified two genomic regions that reduce VTE susceptibility. The first includes the gene for blood coagulation, Factor 3, and its role was confirmed by analyzing mice with an independent mutation in this gene. The second contains a mutation in the Actr2 gene. These findings identify critical genes for the regulation of blood-clotting risk. 21) , and identification of a mutation in the c-Myb gene as a dominant modifier for platelet count in Mpl-deficient mice (congenital thrombocytopenia) (22 . Previously described visible dominant mutant phenotypes (24) , including belly spotting and skeletal abnormalities, were observed in ≈5.9% of G1 offspring, similar to the ∼4.2% rate of observable mutants in previous studies (24) . This is consistent with the ∼20-30 functionally significant mutations per G1 mouse expected with this ENU mutagenesis protocol (25) . Although 25% of G1 embryos from this cross are expected to carry the synthetic lethal F5 L/L Tfpi +/− genotype, most are lost at birth. Given a total of 6,631 G1s for the other three genotypes observed at weaning (∼1/3 ) (Fig. 1D ), and this difference was maintained after outcrossing to the 129S1 strain (Fig. 1E) .
Previous reports based on gene function in the specific-locus test estimate an ENU-induced mutation rate of 1/700 loss-of-function mutations per locus for the ENU dosing regimen used here (26) . This mutation rate predicts that our screen of 6,729 G1 progeny (2,210 F5 L/L Tfpi +/− expected) should have produced approximately three mutations per gene averaged over the entire genome, with 54% of these mutations expected to be null (16) , resulting in 1.5× genome coverage for loss-of-function mutations. informative offspring, respectively, genotyping for a total of ∼800 markers in each cross failed to identify any loci with a logarithm of the odds (LOD) score greater than or equal to 3.3 (maximum LODs for MF5L1 = 1.15, MF5L9 = 2.5, and MF5L16 = 1.61). Although we cannot exclude cosegregation of more than one suppressor mutation, the absence of a clear linkage signal for each of these lines likely reflects complex mouse strain modifier gene interactions, which are known to significantly impact mouse phenotypes (10, 27) and confound linkage analysis (28) . Consistent with this hypothesis, we have previously documented poorer survival to weaning in mixed B6-129S1 F5 L/L mice compared with littermates (14) . We extended these observations by the analysis of additional F5 L/+ and F5 L/L littermates, with mice of the F5 L/L genotype demonstrating a 50% reduction in survival in the 129S1 versus B6 strain backgrounds (Table S1 ).
MF5L6 was maintained for 12 generations on both the mixed and B6 backgrounds and produced a total of 336 F5 L/L Tfpi +/− mice (98 on the mixed B6-129S1 background and therefore useful for linkage analysis; see Table 1 ). Genome-wide SNP genotyping was performed on DNA from these 98 genetically informative F5 L/L Tfpi +/− mice; multipoint linkage analysis is shown in Fig. 2A . Since the genetic intervals around the F5 and Tfpi loci cannot be accurately assessed for linkage, these regions of chromosomes (Chr) 1 and 2 were excluded from linkage analysis (Materials and Methods and Fig. 2A) . A single locus with a significant LOD score of suppresses the synthetic lethal F5 L/L Tfpi +/− phenotype with incomplete penetrance (33%) that also differs by sex (10% for males and 67% for females). In contrast, the MF5L6 line exhibited an overall penetrance of 72.4%, with similar male/female penetrance. Gender-specific differences in venous thrombosis rates have previously been reported, including contributions from oral contraceptives and hormone replacement therapy (29) (30) (31) . This difference in penetrance could be due to 129S1 strain effects in the MF5L6 line or differences between a F3 regulatory mutation in MF5L6 compared with the F3 loss-of-function allele used here.
Whole-exome sequencing data analysis of a F5 L/L Tfpi +/− mouse from MF5L6 failed to identify an ENU variant in F3 or in any other genes in the nonrecombinant interval or more broadly on the entire Chr3. This is a particularly gene-rich region (Fig. 2B) , and errors in annotation could obscure the responsible variant. Of note, this interval also includes Slc44a3, a paralog of Slc44a2, the latter previously identified as a potential modifier of VTE risk in humans (6) . Although additional ENU variants were identified on other chromosomes, none cosegregated with the survival phenotype in line MF5L6 (Table S2) . Sanger sequencing analysis of the full set of F3 exons and introns, as well as 5 kb upstream of exon 1, also failed to identify an ENU-induced mutation. In addition, analysis of F3 mRNA levels in liver, lung, and brain tissues of adult mice failed to identify any differences in the level of expression from the ENUmutant compared with the WT allele (Fig. S1) .
Taken together, these data suggest that an ENU-induced F3 regulatory mutation outside the sequenced segment may be responsible for thrombosuppression in MF5L6, although we cannot exclude a regulatory mutation in another gene. Nonetheless, our findings demonstrate that F3/Tfpi balance plays a key role in thrombosis in the mouse, particularly in the setting of F5 L , and suggest that modest variations in either F3 or Tfpi could be important modifiers of VTE susceptibility in humans. mouse (from the G2-G5 generation) from each of eight MF5L lines, including the four lines described above and four additional lines with large pedigrees (MF5L5, MF5L8, MF5L11, MF5L12). The mean coverage of sequenced exomes was more than 90×, with >97% of the captured region covered with at least six independent reads (Table S3) . A total of 125 heterozygous variants were identified as candidate suppressor mutations, with 79 variants affecting protein sequence (Table S2) . Of the total mutations, 54.4% were nonsynonymous single-nucleotide variants (SNVs), followed by UTRs (17.6%) and synonymous (14.4%) and stopgain SNVs (7.2%), with the remainder being comprised of indels, splicing, and stop-loss mutations. The most common mutation events were A/T→G/C transitions (35.3%), while C/G→G/C transversions were the least represented (2.5%). This spectrum of mutations is consistent with previously published ENU experiments (32) . Variants exhibiting no recombination with the Tfpi locus on Chr2 (17 variants) were excluded from further analysis (Materials and Methods). Sanger sequencing confirmation was performed for 62 variants, including all nonsynonymous and stopgain mutations. These variants were then checked for parent of origin (either the G1 mutagenized progeny or its nonmutagenized mate) as well as the original mutagenized G0 male. Forty-seven of these variants were identified in the G1 mouse but not in the G0 or nonmutagenized parent, consistent with ENU-induced mutations. The remaining 15 mutations were NGS sequencing errors (11/15), de novo mutations (2/15) or mutations transmitted from the nonmutagenized parent (2/15) (Table S2) . Each SNV was analyzed in additional MF5L mice from the line in which it was identified. None of the thrombosuppressive exonic ENU-induced variants identified in lines MF5L1, 5, 6, 8, 9, 11 , and 16 segregated with the lethal phenotype as tested by KaplanMeier analysis using a significance threshold of P < 0.05 (33) . Of the seven candidate ENU-induced SNVs identified from wholeexome sequence analysis for the MF5L12 line, one was an NGS sequencing error, and six were validated by Sanger sequencing as consistent with ENU-induced mutations in the G0 mice (Table  S2) ) (Fig. 3A ).
Actr2 as a Thrombosuppressor Gene. The gene Actr2 encodes the ARP2 protein, which is an essential component of the Arp2/3 complex (34). ARP2 along with ARP3 and five other independent protein subunits (ARPC1-5) form the evolutionarily conserved seven-subunit Arp2/3 complex (35) . Arp2/3 is a major component of the actin cytoskeleton and is found in most eukaryotic cells, including platelets (36) . Arp2/3 binds to the sides of actin filaments and initiates the growth of a new filament, leading to the creation of branched actin networks that are important for many cellular processes (37) . Loss of Arp2/3 function can have severe consequences, as illustrated by the embryonic lethality of mice homozygous for an ARP3 hypomorph (38) . In hemostasis, the Arp2/3 complex is necessary for actin-dependent platelet cytoskeletal remodeling events, which are essential for platelet activation and degranulation (37, 39, 40) . The Actr2 +/G mutation results in a p.R258G substitution in exon 7 of Actr2 at a highly conserved amino acid position, with arginine present at this position for all 60 available vertebrate sequences (https://genome.ucsc.edu), as well as in plants and fungi (Fig. 3B) . In addition, no variants at this position have been identified to date in over 120,000 human alleles (41).
Actr2 Hemizygosity Is Incompatible with Survival. We attempted to generate an independent Actr2 knockin (Actr2 Table S4 ). Although highly efficient gene targeting was observed in blastocysts (Fig. S3) , transfer of 275 injected embryos into foster mothers resulted in no surviving pups with a successfully targeted Actr2 allele. These data suggest that heterozygous loss of function for Actr2 may be incompatible with survival to term. Consistent with this hypothesis, human sequencing data from the Exome Aggregation Consortium (ExAC), which includes 60,706 individual exomes, reports a probability of loss-of-function intolerance for ACTR2 of 0.997 (41) . ACTR2 mutations have not been previously associated with human disease (https://omim.org/entry/604221) (42), again as is consistent with early embryonic lethality. In addition, of 373,692 mouse ENU-induced mutations listed in the Mutagenetix website (https:// mutagenetix.utsouthwestern.edu/), only 16 are located in the Actr2 gene, with no predicted loss-of-function mutations (43) . Taken together, these data strongly suggest that haploinsufficiency for Actr2 is not tolerated in humans or mice. The viability of Actr2 +/G mice suggests that the Actr2 G allele is either hypomorphic or a unique gainof-function mutation distinct from simple haploinsufficiency. Similarly, analysis of ExAC data suggests that four of the six other members of the Arp2/3 complex are intolerant of heterozygous loss of function in humans (41) . Our findings suggest that subtle alterations in Actr2 function, and potentially in other components of the actin cytoskeleton, could alter hemostatic balance and play a previously unappreciated role in thrombosis susceptibility.
The identification of novel factors involved in the regulation of hemostasis is challenging; genes leading to marked shifts in hemostatic balance resulting in either severe bleeding or thrombosis are straightforward to identify clinically in humans, whereas subtle shifts are likely to escape detection given the multiple layers of buffering built into the complex hemostatic system (10). Homozygous deficiency (which would not be tested by our dominant suppressor strategy) for a number of hemostatic factors results in clinical bleeding, whereas heterozygous carriers remain asymptomatic. Although a single mutation in the X-chromosomal Factor VIII (or IX) gene produces severe bleeding in humans and rescues the lethal F5 L/L Tfpi +/− mouse phenotype (Fig. 1A) , an F8 gene mutation would not be transmitted from the ENU-mutagenized male to male offspring and thus would be undetected. Indeed, the dominant sensitized suppressor screen reported here was undertaken to identify genes for which a modest (≤50%) reduction in function would significantly shift the overall hemostatic balance. Such loci represent likely candidates for common human variation contributing to thrombosis and bleeding disorders. Gene variants with subtle yet significant antithrombotic effects represent attractive therapeutic targets because of a potentially wide therapeutic window with few unintended side effects. The finding of 98 F5 L/L Tfpi +/− mice carrying putative thrombosis suppressor mutations (at an estimated 1.5× genome coverage) suggests that subtle alterations at a number of loci are capable of suppressing the F5 L/L Tfpi +/− lethal thrombotic phenotype. The complex strainspecific genetic modifiers that confounded the genetic linkage analysis are consistent with this model. Nonetheless, our findings illustrate the particular importance of the F3/Tfpi axis in thrombosis regulation (especially in the setting of F5 L ) as well as the identification of Actr2 and the Arp2/3 complex as another potentially sensitive regulatory pathway for maintaining hemostatic balance.
Materials and Methods
The University of Michigan Institutional Committee on the Use and Care of Animals approved all experiments using mice (protocol numbers PRO00007371, PRO00005191, and PRO00005913). Detailed descriptions of mouse strains and procedures for ENU mutagenesis, breeding, genetic mapping and genotyping, Sanger and whole-exome sequencing, estimation of F3 allelic expression, generation of Actr2 CRISPR/Cas9-targeted mice and cells, the SURVEYOR nuclease assay, and statistical data analyses are provided in Supporting Information. Primers used in these studies are listed in Table S5 .
